ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Immunoglobulins (Ig)"

  • 2018 American Transplant Congress

    Comparison of C1Q Binding and Flow Cytometric Crossmatch Results Provides an Accurate Evaluation of Hypersensitive Kidney Transplant Patients

    E. Eksioğlu-Demiralp,1 A. Türkmen,2 B. Yelken,2 S. Görçin,2 O. Elbasi,1 F. Yalçin,3 B. Koçak,2 C. Karatas,4 M. Tuncer,4 M. Altinel.3

    1Tissue Typing and Immunology Laboratory, Memorial Health Group, Istanbul, Turkey; 2Sisli Hospital Transplantation Unit, Memorial Health Group, Istanbul, Turkey; 3Hizmet Hospital Transplantation Unit, Memorial Health Group, Istanbul, Turkey; 4Atasehir Hospital Transplantation Unit, Memorial Health Group, Istanbul, Turkey.

    Measurement of C1q binding to Donor specific antibodies (DSA) gives transplantation chance to hypersensitive patients having non-binding high amount of anti-HLA antibodies. In our series…
  • 2018 American Transplant Congress

    Temporal Variability of IgG Subclasses

    D. Pinelli, M. Gopalakrishnan, A. Joong, P. Thrush, A. Tambur.

    Northwestern University, Chicago; Lurie Children's Hospital, Chicago.

    The temporal model of IgG subclass switching supports sequential IgG conversion; however, the diversity of previously stimulated B cells is known to shape responses in…
  • 2018 American Transplant Congress

    The Results of Plasmapheresis and Anti-CD20 Based Desensitization without Intravenous Immunoglobulin in Positive Crossmatch Kidney Transplants

    H. Kwon, Y. KIm, J. Choi, S. Shin, J. Jung, M. Cho, J. Kim, D. Han.

    Asan Medical Center, Seoul, Korea.

    This study examined the mid-term clinical outcomes in positive crossmatch kidney transplants (XMKT) for patients who received desensitization with plasmapheresis (PP) and anti-CD20 based regimens…
  • 2017 American Transplant Congress

    A Low-Dose Anti-Hepatitis B Immunoglobulin Regimen for Prophylaxis of Hepatitis B Recurrence.

    W.-C. Lee, Y.-C. Wang, C.-H. Cheng, T.-H. Wu, C.-F. Lee, T.-J. Wu, H.-S. Chou, K.-M. Chan.

    Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan

    Background: Hepatitis B virus (HBV)-related liver disease is the major indication of liver transplantation in Asian countries. Combination of anti-hepatitis B immunoglobulin (HBIg) and anti-viral…
  • 2017 American Transplant Congress

    Improving Value by Standardizing the Use of IVIG Amongst Pediatric Solid Organ Transplant (SOT) Patients.

    J. Sawyer,1 J. Bucuvalas,2 L. Danziger-Isakov,3 J. Gossett,3 L. Burkhart,3 A. Lorts.3

    1Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati; 2Division of Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati; 3Solid Organ Transplant Center, Cincinnati Children's Hospital Medical Center, Cincinnati

    Background: Given the high cost of pharmaceuticals (i.e. IVIG), we sought to determine if unnecessary variation in drug use may be an opportunity to improve…
  • 2017 American Transplant Congress

    Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).

    B.-H. Shin,1 M. Everly,2 J. Choi,1 S. Ge,1 A. Petrosyan,1 A. Vo,1 S. Jordan,1 M. Toyoda.1

    1Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Terasaki Foundation Laboratory, Los Angeles

    Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use…
  • 2017 American Transplant Congress

    Hypogammaglobulinemia in Pediatric Heart Transplant Candidates Is Not Corrected by Transplantation.

    R. Madan,1 R. Penkert,2 J. Dara,1 J. Lamour,1 B. Herold,1 J. Hurwitz.2

    1Pediatrics, Albert Einstein College of Medicine and The Children's Hospital at Montefiore, Bronx, NY; 2Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN

    Introduction: Hypogammaglobulinemia (HG) is associated with poor outcomes in adult heart transplant recipients but is not well studied in pediatric recipients. We therefore investigated longitudinal…
  • 2016 American Transplant Congress

    HLA Antibody Clonality and Epitopes Dictate Complement Activation.

    K. Thomas,1 N. Valenzuela,1 A. Mulder,2 E. Reed.1

    1Pathology and Laboratory Medicine, UCLA, Los Angeles, CA; 2Leiden University Medical Center, Leiden, Netherlands.

    Background: Alloimmunization results in production of polyclonal donor specific antibodies (DSA) against human leukocyte antigens (HLA), which mediate endothelial cell activation, leukocyte recruitment, and complement…
  • 2016 American Transplant Congress

    Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.

    E. Woodle, M. Pando Rigal, S. Tremblay, A. Girnita.

    U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.

    Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…
  • 2016 American Transplant Congress

    Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).

    R. Knight,1 S. Patel,1 J. Loucks-DeVos,2 S. Kuten,1 A. Gaber.1

    1Houston Methodist Hospital, Houston, TX; 2Kansas University Medical Center, Kansas City, KS.

    Intravenous immune globulin (IVIG) may be beneficial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences